UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Drug discovery today, ISSN 1359-6446, 07/2005, Volume 10, Issue 13, pp. 917 - 925
Schizophrenia | positive symptoms | limbic system | extrapyramidal | cognition | cocaine | Pharmaceutical technology. Pharmaceutical industry | Biological and medical sciences | Medical sciences | General pharmacology | Pharmacology. Drug treatments | Humans | Dopamine Antagonists - therapeutic use | Technology, Pharmaceutical - methods | Tetrahydroisoquinolines - therapeutic use | Substance-Related Disorders - physiopathology | Technology, Pharmaceutical - trends | Animals | Substance-Related Disorders - prevention & control | Receptors, Dopamine D3 - physiology | Molecular Structure | Receptors, Dopamine D3 - antagonists & inhibitors | Dopamine Antagonists - chemistry | Nitriles - therapeutic use | Index Medicus
Journal Article
European journal of clinical pharmacology, ISSN 0031-6970, 11/2012, Volume 68, Issue 11, pp. 1465 - 1472
Biomedicine | Buspirone | Pharmacology/Toxicology | Randomised clinical trial | Antiemetic | Postoperative nausea and vomiting | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Biological and medical sciences | Pharmacology. Drug treatments | Medical sciences | Anti-Anxiety Agents - administration & dosage | Injections, Intravenous | Buspirone - blood | Dopamine Antagonists - pharmacokinetics | Humans | Middle Aged | Receptors, Dopamine D3 - metabolism | Antiemetics - administration & dosage | Male | Buspirone - pharmacokinetics | Receptors, Dopamine D2 - metabolism | Dopamine Antagonists - administration & dosage | Incidence | Dose-Response Relationship, Drug | Young Adult | Anti-Anxiety Agents - pharmacokinetics | Buspirone - administration & dosage | Antiemetics - pharmacokinetics | Antiemetics - therapeutic use | Aged, 80 and over | Adult | Anti-Anxiety Agents - adverse effects | Antiemetics - adverse effects | Female | Anti-Anxiety Agents - therapeutic use | Buspirone - adverse effects | Receptors, Dopamine D3 - antagonists & inhibitors | Buspirone - therapeutic use | Receptor, Serotonin, 5-HT1A - metabolism | Postoperative Nausea and Vomiting - epidemiology | Double-Blind Method | Dopamine Antagonists - therapeutic use | Serotonin 5-HT1 Receptor Agonists - therapeutic use | Serotonin 5-HT1 Receptor Agonists - adverse effects | Postoperative Nausea and Vomiting - prevention & control | Receptor, Serotonin, 5-HT1A - chemistry | Buspirone - analogs & derivatives | Dopamine Antagonists - adverse effects | Serotonin 5-HT1 Receptor Agonists - administration & dosage | Aged | Dopamine D2 Receptor Antagonists | Postoperative Nausea and Vomiting - blood | Prevention | Complications and side effects | Buspirone hydrochloride | Adults | Nausea | Analysis | Postoperative period | Vomiting | Clinical trials | Pharmacology | Drug therapy | Clinical outcomes | Index Medicus
Journal Article
Bioorganic & medicinal chemistry letters, ISSN 0960-894X, 10/2012, Volume 22, Issue 19, pp. 6039 - 6047
GPCR structures | Obesity | Melanin concentrating hormone (MCH) | MCHR1 antagonists | hERG | Chemometric analysis | Physical Sciences | Chemistry | Chemistry, Organic | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Chemistry, Medicinal | Science & Technology | Biological and medical sciences | Pharmacology. Drug treatments | Medical sciences | Naphthalenes - chemistry | Piperidines - chemistry | Obesity - drug therapy | Humans | Models, Molecular | Crystallography, X-Ray | Structure-Activity Relationship | Pyrimidines - pharmacology | Biphenyl Compounds - therapeutic use | Anti-Obesity Agents - therapeutic use | Pyrimidines - chemistry | Naphthalenes - pharmacology | Ether-A-Go-Go Potassium Channels - antagonists & inhibitors | Anti-Obesity Agents - chemistry | Biphenyl Compounds - pharmacology | Piperidines - pharmacology | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Drug Design | Receptors, Somatostatin - antagonists & inhibitors | Molecular Structure | Biphenyl Compounds - chemistry | Anti-Obesity Agents - pharmacology | Naphthalenes - therapeutic use | Hormones | Drug therapy | Free radicals (Chemistry) | Analysis | Index Medicus | Indexing in process
Journal Article
Neuroscience, ISSN 0306-4522, 2012, Volume 215, pp. 196 - 208
Neurology | GABA | 5HT | neuropathic pain | spinal cord stimulation | noradrenaline | dopamine | Dopamine | Noradrenaline | Spinal cord stimulation | Neuropathic pain | Neurosciences | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Fundamental and applied biological sciences. Psychology | Vertebrates: nervous system and sense organs | Biological and medical sciences | Pain Threshold - physiology | Baclofen - analogs & derivatives | Phentolamine - therapeutic use | Propranolol - therapeutic use | Electrodes - adverse effects | Adrenergic alpha-Antagonists - therapeutic use | GABA Antagonists - therapeutic use | Bicuculline - therapeutic use | Adrenergic beta-Antagonists - pharmacology | Time Factors | Pain Threshold - drug effects | Female | Neuralgia - physiopathology | Baclofen - therapeutic use | Disease Models, Animal | Sulpiride - therapeutic use | Ketanserin - therapeutic use | Rats | Serotonin Antagonists - therapeutic use | Methysergide - therapeutic use | Rats, Sprague-Dawley | Hyperalgesia - physiopathology | Pain Measurement - methods | Animals | Hyperalgesia - therapy | Analysis of Variance | Dopamine Antagonists - pharmacology | Spinal Cord - physiology | Neuralgia - therapy | Transcutaneous Electric Nerve Stimulation - methods | Physiological aspects | Index Medicus | Medicin och hälsovetenskap
Journal Article
Psychiatry and clinical neurosciences, ISSN 1323-1316, 06/2015, Volume 69, Issue 6, pp. 321 - 334
first‐generation agents | schizophrenia | management | second‐generation agents | tardive dyskinesia | second-generation agents | first-generation agents | Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Psychiatry | Science & Technology | Stilbenes - therapeutic use | Antipsychotic Agents - adverse effects | Humans | Propranolol - therapeutic use | Leucine - therapeutic use | Dopamine Agents - therapeutic use | Amantadine - therapeutic use | Piracetam - therapeutic use | Pyridoxine - therapeutic use | Clonazepam - therapeutic use | Drugs, Chinese Herbal - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Adrenergic Uptake Inhibitors - therapeutic use | Anticonvulsants - therapeutic use | Nootropic Agents - therapeutic use | Isoleucine - therapeutic use | Vitamins - therapeutic use | Ginkgo biloba | alpha-Tocopherol - therapeutic use | Antioxidants - therapeutic use | Movement Disorders - etiology | Piracetam - analogs & derivatives | Melatonin - therapeutic use | Fatty Acids, Omega-3 - therapeutic use | Valine - therapeutic use | Isoxazoles - therapeutic use | Plant Extracts - therapeutic use | Movement Disorders - drug therapy | Tetrabenazine - therapeutic use | Schizophrenia | Movement disorders | Tardive dyskinesia | Medical research | Index Medicus
Journal Article
Expert review of neurotherapeutics, ISSN 1473-7175, 02/2016, Volume 16, Issue 2, pp. 131 - 144
Antidepressants | Attention Deficit Hyperactivity Disorder (ADHD) | Amphetamines | Efficacy | Lithium | Adults | Pharmacological Treatment | Metadoxine | Pharmacology & Pharmacy | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Humans | Paroxetine - therapeutic use | Venlafaxine Hydrochloride - therapeutic use | Dopamine Agents - therapeutic use | Droxidopa - therapeutic use | Pyrrolidonecarboxylic Acid - therapeutic use | Adrenergic alpha-Agonists - therapeutic use | Histamine Agents - therapeutic use | Central Nervous System Stimulants - therapeutic use | Desipramine - therapeutic use | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Pyridoxine - therapeutic use | Adult | Lobeline - therapeutic use | Benzhydryl Compounds - therapeutic use | Nomifensine - therapeutic use | Morpholines - therapeutic use | Bupropion - therapeutic use | Pyridines - therapeutic use | Wakefulness-Promoting Agents - therapeutic use | Duloxetine Hydrochloride - therapeutic use | Guanfacine - therapeutic use | Nicotinic Agonists - therapeutic use | Attention Deficit Disorder with Hyperactivity - drug therapy | Antidepressive Agents - therapeutic use | Mecamylamine - therapeutic use | Amphetamines - therapeutic use | Lithium Compounds - therapeutic use | Lisdexamfetamine Dimesylate - therapeutic use | Nicotinic Antagonists - therapeutic use | Quinazolinones - therapeutic use | Memantine - therapeutic use | Drug Combinations | Index Medicus
Journal Article
Nature reviews. Drug discovery, ISSN 1474-1776, 10/2006, Volume 5, Issue 10, pp. 845 - 854
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Biotechnology & Applied Microbiology | Science & Technology | Monoamine Oxidase Inhibitors - therapeutic use | Excitatory Amino Acid Antagonists - therapeutic use | Antiparkinson Agents - pharmacology | Cholinergic Agents - therapeutic use | Humans | Dopamine Agonists - therapeutic use | Serotonin Antagonists - therapeutic use | Clinical Trials as Topic | Parkinson Disease - drug therapy | Adenosine A2 Receptor Antagonists | Antiparkinson Agents - therapeutic use | Serotonin Receptor Agonists - therapeutic use | Narcotic Antagonists - therapeutic use | Index Medicus
Journal Article